stay tuned:
elixi news from the

Enspryng (satralizumab), new treatment for rare autoimmune disease of nerve cells

Enspryng (satralizumab), new treatment for rare autoimmune disease of nerve cells

EMA has recommended granting a marketing authorisation in the European Union (EU) for Enspryng (satralizumab) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adults and adolescents from 12 years of age who are positive for anti-aquaporin-4 antibodies (AQP4-IgG).

NMOSD is a rare and life-threatening condition and most commonly affects the optic nerves and spinal cord. This disorder can lead to reduction or loss of vision, loss of sensation, loss of bowel and bladder control, weakness and paralysis of the arms and legs. NMOSD is thought to be caused by an abnormal reaction of the immune system that causes damage to healthy nerve cells. It is characterised by relapsing attacks, with symptoms coming back periodically. It is estimated that NMOSD affects approximately 1-2 in 100,000 people in the EU.

Enspryng works by reducing and preventing the attacks caused by NMOSD. Satralizumab, the active substance contained in Enspryng, is an antibody designed to block the inflammatory effects of interleukin-6 receptor (IL-6), which is involved in the pathogenesis of the NMOSD.

Enspryng will be available as a pre-filled syringe and will be administered as a solution through an injection under the patient’s skin (subcutaneously). The first three injections are given two weeks apart followed by one injection every four weeks. It can be used on its own or in combination with medicines that reduce the activity of the immune system (immunosuppressive therapy).

In NMOSD, there is inflammation or damage to the optic nerves, spinal cord, and/or brain. The majority of people with NMOSD produce antibodies to a protein called aquaporin-4 (AQP4).

Inflammation is the body’s natural response to foreign organisms and is normally a way to fight infection and promote healing. But in NMOSD, the body’s immune system mistakes normal tissue in the CNS as something harmful and begins to attack the optic nerves and spinal cord, causing symptoms and injury.

Repeated inflammation within the CNS can result in relapses that may be severe and unpredictable. During a relapse, new damage to the optic nerves and/or spinal cord can occur.

Share this article

Pin it

SEE Also

we are specialized in the procurement and distribution of pharmaceutical products, medical devices all over the world

Stay Tuned

Subscribe to our newsletter


    Elixi International SA
    Vicolo Oldelli 12
    6830 Chiasso (TI)


    Tel.  +41 (0)91 6822040


    Elixi Europe Srl
    Via Uberti 6
    21100 Varese (VA)


    Tel.  +41 (0)91 6822040


    Elixi Pharma pte. ltd.
    6A  Shenton way #04-01
    Downtown gallery building


    Tel.  +41 (0)91 6822040

    ELIXI International SA

    Copyright 2023 ELIXI International SA.   |   All Rights Reserved   |   Privacy Policy   |   Cookie Policy